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Abstract
Nonenzymatic glycation of proteins occurs at an accelerated
rate in diabetes and can lead to the formation of advanced gly-
cation end products of proteins (AGEs), which bind to mononu-
clear phagocytes (MPs) and induce chemotaxis. Wehave iso-
lated two cell surface-associated binding proteins that mediate
the interaction of AGEs with bovine endothelial cells. One of
these proteins is a new member of the immunoglobulin super-
family of receptors (termed receptor for AGEsor RAGE); and
the second is a lactoferrin-like polypeptide (LF-L). Using
monospecific antibodies to these two AGE-binding proteins, we
detected immunoreactive material on Western blots of deter-
gent extracts from human MPs. Radioligand-binding studies
demonstrated that antibody to the binding proteins blocked
'25I-AGE-albumin binding and endocytosis by MPs. Chemo-
taxis of human MPsinduced by soluble AGE-albumin was pre-
vented in a dose-dependent manner by intact antibodies raised
to the AGE-binding proteins, F(ab')2 fragments of these anti-
bodies and by soluble RAGE. WhenMPmigration in response
to N-formyl-Met-Leu-Phe was studied in a chemotaxis
chamber with AGE-albumin adsorbed to the upper surface of
the chamber membrane, movement of MPs to the lower com-
partment was decreased because of interaction of the glycated
proteins with RAGEand LF-L on the cell surface. The capacity
of AGEs to attract and retain MPs was shown by implanting
polytetrafluoroethylene (PTFE) mesh impregnated with AGE-
albumin into rats: within 4 d a florid mononuclear cell infiltrate
was evident in contrast to the lack of a significant cellular re-
sponse to PTFEwith adsorbed native albumin. These data indi-
cate that RAGEand LF-L have a central role in the interaction
of AGEs with human mononuclear cells and that AGEs can
serve as a nidus to attract MPs in vivo. (J. Clin. Invest. 1993.
91:2155-2168.) Key words: monocyte * glycation * diabetes * ath-
erosclerosis
Introduction
The extended interaction of proteins with aldose sugars, such
as glucose or ribose ( 1-3), leads to the formation of advanced
glycation end products of proteins (AGEs).' AGEs bind to
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1. Abbreviations used in this paper: AGE, advanced glycation end prod-
uct; EBSS, Earle's balanced salt solution; EC, endothelial cell; LF-L,
lactoferrin-like; MP, mononuclear phagocyte; PTFE, polytetrafluoro-
ethylene; RAGE, receptor for AGE; sRAGE, soluble RAGE.
endothelial cells (ECs) and mononuclear phagocytes (MPs)
and alter cellular functions. Exposure of cultured ECs to AGEs
perturbs barrier and coagulant function of the cell monolayer
and stimulates cell growth (4, 5). MP-AGEinteraction leads
to cell activation, as evidenced by the induction of MPmigra-
tion, as well as release of cytokines and platelet-derived growth
factor (6, 7).
The accumulation of AGEs in the vessel wall, especially in
diabetes, where their capacity to perturb endothelial and MP
functions may contribute to the development of vascular le-
sions, has prompted several investigators to study interactions
of AGEswith macrophages and endothelial cells (8-12). Ra-
doff et al. (9) and Yang et al. ( 1) identified two cell surface
proteins on rodent macrophages that may be involved in the
cellular interaction with AGEs: a 90-kD polypeptide that inter-
acts with furanyl-furoyl-imidazole (a synthetic compound pos-
sibly related to AGEs) (9) and a 60-kD polypeptide that reacts
directly with AGE-albumin ( 11 ). Wehave isolated and charac-
terized two polypeptides from extracts of bovine lung on the
basis of their ability to bind AGEs: a protein that is a new
member of the immunoglobulin superfamily of receptors
(termed receptor for AGEs or RAGE) and a lactoferrin-like
(LF-L) AGE-binding protein (8, 10). RAGEand the LF-L
polypeptide are both present on the surface of bovine ECs, and
specific antibodies to each of these polypeptides block the bind-
ing of '251-AGE-albumin to ECs (10).
In this study, we have identified RAGEand the LF-L
AGE-binding protein in human MPsand have demonstrated
that these polypeptides mediate the binding and endocytosis of
'251-AGE-albumin by MPs. Whereas engagement of these poly-
peptides by soluble AGE-albumin induces MPchemotaxis, in-
teraction of these MPcell surface receptors with immobilized
AGEs slows their migration. These results demonstrate that
RAGEand the LF-L AGEbinding protein have a central role
in mediating the effects of AGEson MPsand suggest that solu-
ble AGEscould attract MPsinto vessel walls and tissues, where
deposits of immobilized AGEs could lead to their retention.
This work outlines a possible mechanism, in addition to the
formation of oxidized lipoproteins ( 13), through which modi-
fied proteins can draw monocytes into the vessel wall.
Methods
Preparation of human MPs. Humanperipheral blood monocytes were
isolated from the blood of normal healthy volunteers ( 13 ). Blood was
centrifuged on Histopaque 1077 (Sigma Chemical Co., St. Louis,
MO), the mononuclear cell fraction was obtained, washed twice in
Earle's balanced salt solution (EBSS), resuspended in RPMI 1640 con-
taining human serum (10%; Gemini, Calabasas, CA), plated on 100-
mmtissue culture dishes, and incubated at 37°C for 1-2 h. Nonadher-
ent cells were removed by washing the plate twice with EBSS and
adherent cells were harvested by incubation with calcium-magnesium-
free EBSScontaining EDTA(2 mM)for 15 min at 370C followed by
extensive washing in EBSSand resuspension in RPMI 1640 containing
human serum (10%) at a concentration of 106 cells/ml (10).
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Preparation ofglycatedproteins in vitro, AGE-bindingproteins, and
antibodies. AGEalbumin was prepared by incubating bovine serum
albumin (fraction V; Sigma Chemical Co.) with either glucose-6-phos-
phate (250 mM; Sigma Chemical Co.), glucose (0.5 M; Sigma Chemi-
cal Co.), or ribose (250 mM;Sigma Chemical Co.) at 370C for 6-8 wk.
Glycated proteins were characterized by their identical binding proper-
ties to ECs and purified AGE-binding proteins, as reported previously
(5, 10), and by their fluorescence (1). Isoelectric focusing demon-
strated that the pIs were very similar for AGE-albumin prepared in the
presence of either glucose, ribose, or glucose-6-phosphate (pI 4.55)
(the pl of native albumin was 4.7-4.9), and SDS-PAGEshowed a
single major band. Collagen I (Collaborative Research, Bedford, MA)
was glycated using the same procedure. Controls consisted of the same
initial preparations of albumin and collagen I incubated at 370C in an
identical fashion, except that aldoses were omitted from the reaction
mixture. Radiolabeling of albumin/AGE-albumin was accomplished
by the lactoperoxidase method using Enzymobeads (Bio-Rad Laborato-
ries, Richmond, CA), and the final specific radioactivity of the tracers
was 1.5 X 103 cpm/ng (10).
AGE-binding proteins were purified to homogeneity from a deter-
gent extract of bovine lung acetone powder ( 10). RAGEmigrated as a
single band on reduced and nonreduced SDS-PAGEwith a relative
molecular mass of 35 kD. This form of RAGEhas been termed
soluble RAGE(sRAGE), as it probably represents the amino terminal
two thirds of the molecule (8). Before use in chemotaxis assays,
sRAGEwas dialyzed versus PBScontaining octyl-fl-glucoside (0.0 1%).
Purified LF-L AGE-binding protein also migrated as a single band on
SDS-PAGEwith a relative molecular mass of 80 kD (10). Antibod-
ies prepared to each of the AGE-binding proteins in rabbits and guinea
pigs have been shown to be monospecific, on the basis of Western
blotting studies in which antibody staining of a single protein in EC
(10) or partially purified lung (data not shown) extracts could be
blocked by addition of the respective, purified, soluble AGE-binding
protein. Antisera were chromatographed on protein A-agarose to pu-
rify the IgG fraction. In addition, for the LF-L AGE-binding protein,
antibody was affinity purified on a lactoferrin-affi-gel 10 column. Lac-
toferrin (100 mg; Sigma Chemical Co.) was bound to affi-gel 10 (25 ml;
Bio-Rad Laboratories, Sacramento, CA) according to the manufac-
turer's instructions (coupling efficiency 90%). Anti-LF-L serum (5
ml) was applied to the lactoferrin-affi-gel 10 (25 ml), and after exten-
sive washing the adsorbed immunoglobulins were eluted with glycine
buffer (0.2 M; pH 2.5). The eluate was rapidly neutralized with Tris to
pH 7.4 and then dialyzed versus Tris-buffered saline (Tris, 20 mM,pH
7.4; NaCl 0.1 M). As a control for experiments employing anti-AGE-
binding protein antibodies, studies were performed with polyclonal
rabbit anti-human CD4 IgG (this antibody was generously provided
by Dr. Seth Lederman, Department of Medicine.) This antiserum was
prepared by immunizing rabbits by standard methods with purified
recombinant human CD4(14), generously provided by Biogen (Cam-
bridge, MA), and shown to be present on the surface of human MPs
( 15). The IgG fraction was purified as above and found to be monospe-
cific for CD4, on the basis of Western blotting of Jurkat T cell lysates.
In addition, this immune IgG stains the surface of monocytoid cells by
FACS analysis and immunoprecipitates CD4 from Jurkat T cell ly-
sates.
F(ab')2 fragments of the immune IgG raised to RAGEand LF-L
AGE-binding protein were prepared by pepsin digestion of IgG frac-
tions for 6 h at 37°C (5 ytg pepsin/mg of IgG in 100 mMsodium citrate
buffer). The reaction was stopped by the addition of I / 10 vol of Tris ( 3
M; pH 8.8), followed by centrifugation at 10,000 gfor 30 min, and the
digest was dialyzed against PBS. F(ab')2 fragments were separated from
other components of the reaction mixture using a protein A-Sepharose
CL-4B (Pharmacia Inc., Piscataway, NJ) column. The pass-through
was collected, and the purity of the F(ab')2-containing fractions was
determined by SDS-PAGE. To test the effect of intact antibodies or
their F(ab')2 fragments in chemotaxis assays, suspensions of mono-
cytes ( 106/ml) were preincubated for 1 h in RPMI 1640 containing
fetal bovine serum (1%) and the indicated immune IgG, F(ab')2 or
nonimmune guinea pig IgG at 40C. Cells were then washed twice in
EBSS and resuspended in RPMI 1640 containing fetal bovine serum
(1%) at a concentration of 2 X I05 cells/ml for chemotaxis assays.
Antibodies to AGE-moieties on proteins were prepared by immu-
nizing guinea pigs with AGE-albumin or AGE-keyhole limpet hemo-
cyanin and affinity purifying the antibody population that selectively
recognized AGEs (not the native protein backbone) through sequen-
tial chromatography on columns with immobilized native protein and
then AGE-moiety. (Yan, S. D., A. M. Schmidt, J. Brett, and D. Stern,
manuscript is in preparation concerning the characterization of the
anti-AGE antibodies) This population of antibodies was used to de-
velop an ELISA assay for AGEs. In brief, ELISA wells were coated with
a range of concentrations of AGEalbumin (0.025-250 ,g per well)
overnight at 40C in carbonate buffer (pH 9). Wells were washed three
times (0.1 ml per wash) with Dulbecco's PBS containing Tween 20
(0.05%), excess sites in the well were blocked by incubation with goat
serum ( 1%) in PBSfor 2 h at 370C, and then wells were washed again as
above. A range of dilutions of patient plasma, either that derived from
healthy volunteers (< 41 yr) or individuals with diabetes, was added to
wells along with a standard concentration of antibody ( 1:1,600 dilu-
tion) for 2 h at 370C. Wells were then washed, secondary antibody was
added, peroxidase-conjugated goat anti-guinea pig IgG (Sigma Chemi-
cal Co.), for I h at 370C and O-phenylenediamine (Sigma Chemical
Co.) was used to visualize bound antibody. The reaction was stopped
with sulfuric acid and OD495 was determined. This ELISA was used to
select diabetic plasma from which AGEs were isolated as described
below. By immunofluorescence, anti-AGE antibodies did not specifi-
cally stain human MPs.
The anti-AGE antibody was also coupled to affi-gel 10 according to
the manufacturer's instructions, and then the resin was incubated with
plasma from diabetics (plasma of two patients with diabetes, which
contained AGEsby ELISA, was pooled) or normal patients (plasma of
two individuals that were negative for AGEs) for 2 h at 370C (20 ml of
plasma/ 10 ml of resin). The resin was washed extensively with Tris
(20 mM;pH 7.4)-buffered saline (0.1 M). Material bound to the resin
was eluted with a high salt (NaCl, 1 M) wash, and the eluate was
dialyzed versus Tris-buffered saline. The latter material was concen-
trated using Centricon tubes (MWCO10,000; Amicon, Beverly, MA),
and protein concentration was determined by standard protein assay
(Bio-Rad). Negligible protein was detectable in the eluate from the
column to which normal plasma had been applied, so that similar
volumes of column eluate were processed in a manner identical to that
for samples from diabetic plasma. This material was used in chemo-
taxis assays with MPs as described below.
Western blotting. For samples blotted with anti-RAGE IgG, human
MPs ( 108 cells) prepared as described above were solubilized in Tris
(20 mM; pH 7.4), NaCI (0.1 M), octyl-,3-glucoside (1%), and PMSF
(1 mM), and chromatographed on hydroxylapatite (10 ml; IBF Bio-
technics, Columbia, MD). The resin was washed extensively with Tris-
buffered saline (Tris, 20 mM, pH 7.4; NaCl, 0.1 M) containing octyl-,B-
glucoside (0.1%) and eluted in the same buffer with the final NaCI
concentration adjusted to 1 M. For samples to be analyzed with anti-
LF-L IgG, the cell pellet was solubilized directly in SDS-PAGEsample
buffer without reducing agent ( 16). In both cases the cell extracts were
then applied to SDS-PAGE(10%) and subjected to Western blotting
by the Blotto procedure ( 17 ) except that membranes containing LF-L
AGE-binding protein were blocked with albumin solution (5%) rather
than nonfat dry milk. After reaction with primary antibody (anti-
RAGEIgG or anti-LF-L IgG), sites of IgG binding were visualized by
chemiluminescence using peroxidase-conjugated secondary antibody
(Amersham Corp., Arlington Heights, IL) or using the same antibody
developed with 3,3'-diaminobenzidine tetrahydrochloride (Sigma
Chemical Co.).
To prove that the two AGE-binding proteins were distinct and not
common subunits of a single receptor, detergent extracts from MPs
( 108 cells, prepared as described above) were chromatographed on im-
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munoaffinity columns with immobilized anti-RAGE IgG or anti-LF-L
IgG. The latter columns were prepared by coupling 15 mg of either
anti-RAGE IgG or anti-LF-L IgG to affi-gel 10. In each case, MPdeter-
gent extract (5 ml) was incubated with anti-RAGE IgG-affi-gel or anti-
LF-L IgG-affi-gel (5 ml in each case) overnight at 4VC. The pass-
through was collected, the resin was then washed extensively in Tris-
buffered saline containing octyl-#-glucoside (0.1%), and the column
was eluted with either NaCI ( 1 M) (anti-RAGE IgG-affi-gel) or glycine
(0.2 M, pH 2.5) (anti-LF-L IgG-affi-gel) (although similar results were
obtained when the anti-RAGE IgG-affi-gel was eluted with acidic gly-
cine buffer, since elution of RAGEwas complete in high salt buffer, the
latter approach was used to enhance stability of the immobilized anti-
bodies, which appeared to deteriorate more rapidly with multiple expo-
sures to acidic conditions). The pass-through and eluted fractions from
each column were dialyzed overnight versus Tris-buffered saline con-
taining octyl-f3-glucoside (0.1%). Fractions were then subjected to
SDS-PAGE(10%) followed by Western blotting with anti-RAGE IgG
and anti-LF-L IgG as above.
Immunofluorescence. Mononuclear cells, isolated as described
above, were allowed to adhere to 12-mm coverslips for 2 h at 370C.
Adherent cells were washed with balanced salt solution and fixed in
paraformaldehyde (2%) in PBS (pH 7.2). Fixed nonpermeabilized
mononuclear cells were incubated with guinea pig anti-RAGE IgG or
anti-LF-L IgG ( 50 ,g/ml) for 60 min at 370C and, after washing,
surface distribution of primary antibody was revealed with FITC-con-
jugated rabbit anti-guinea pig IgG (Sigma Chemical Co.). Where indi-
cated, nonimmune guinea pig IgG replaced immune IgG at the same
concentration as primary antibody.
Assays of radioligand binding and cellular processing of 2SI-AAGE-
albumin by MPs. HumanMPswere plated in 96-well plates (5 X 104
cells per well) in RPMI 1640 containing human serum (10%) and
binding assays were performed within 5 d as follows: cells washed three
times with warm (37°C) HBSSwere incubated with binding buffer
(0.05 ml; MEMcontaining fetal calf serum, 1%) and the indicated
concentration of '25I-AGE-albumin (either radiolabeled glucose-6-
phosphate albumin, glucose albumin, or ribose albumin) alone or in
the presence of an excess of unlabeled AGE-albumin (20-fold molar
excess) or the unlabeled respective aldose sugar (25 mM) for 3 h at
4°C. Binding of '251I-AGE-albumin was terminated by washing cultures
five times with cold HBSS, and cell-bound material was eluted during a
5-min incubation at 37°C with buffer-containing heparin (1 mg/ml)
(5, 10). For assays employing antibodies, IgGs at the indicated dilu-
tions were preincubated with MPsin binding buffer at 4°C for 2 h, cells
were washed in HBSS, and then experiments were performed as above.
Results of binding studies represent the mean±SEof at least quadrupli-
cate determinations. Equilibrium binding data were analyzed by the
equation of Klotz and Hunston ( 18) using nonlinear least-squares anal-
ysis (Enzfitter), as described previously (10).
Cell-associated radioligand was divided into cell surface-bound
and internalized pools on the basis of the following elution techniques.
Binding studies were performed by incubating 1251I-AGE albumin with
MPs(5 x 104 cells per 96 well) for 3 h at 4°C, washing, and then eluting
cell-bound material by 5 min of exposure of cells to Tris-buffered saline
containing either heparin ( 1 mg/ml), sodium acetate (20 mM;pH 2),
dextran sulfate (1 mg/ml), trypsin (0.01 U/ml) or Nonidet P-40
(1%). The amount of cell-associated radioligand eluted by each of
these procedures was comparable and was considered to be bound to
the cell surface. None of these agents altered cell viability or resulted in
detachment of MPs from the plastic surface under these conditions
(except for the detergent, which dissolved the cell monolayer). Similar
experiments were performed after incubation of '251I-AGE albumin
with MPsat 37°C. After elution of cell surface-bound '25I-AGE-albu-
min with heparin or trypsin, as above, the additional pool of radioactiv-
ity eluted by subsequent incubation with Nonidet P-40 (1%) was con-
sidered to be internalized/endocytosed. This was verified morphologi-
cally by studies employing AGE-albumin linked to colloidal gold (see
below).
For internalization experiments, MPs ( 106 cells per well) plated in
24-well tissue culture dishes were washed twice with HBSSand incu-
bated with binding buffer (0.4 ml) containing '251I-AGE-albumin (100
nM; glucose-6-phosphate-albumin) alone or in the presence of a 20-
fold molar excess of unlabeled AGE-albumin for the indicated times at
370C. Whenantibodies to the AGE-binding proteins were used before
warming cultures, MPswere incubated with IgGs for 1 h at 4VC. After
the internalization assay at 370C, MPs were washed five times with
cold HBSS, and heparin-containing elution buffer (0.5 ml) was added
for 5 min at 370C to elute surface-bound tracer. Subsequently, Tris-
buffered saline (Tris, 20 mM, pH 7.4; NaCl, 0.1 M) containing Noni-
det P.40 (1%) was added for 5 min at 370C to release the internalized
pool of radioligand.
Surface binding and cellular uptake of AGE-albumin gold conju-
gates. AGE-albumin (glucose-6-phosphate albumin) colloidal gold
conjugates were prepared and used by the general method described
previously ( 19, 20). In brief, suspensions of colloidal gold were pre-
pared (21 ) with an average diameter of 25 nm (22) and conjugated to
albumin at pH 6.0. Complete surface labeling was achieved as deter-
mined by the serial electrolyte test (23) and labeled colloids were evalu-
ated for stability as previously described (24). Experiments with gold-
labeled AGE-albumin were carried out according to the same general
protocols outlined above for radiolabeled AGE-albumin. After binding
of gold particles to the surface, unbound particles were removed by
washing (in certain cases, bound particles were removed by heparin
elution), and samples were prepared for electron microscopy: samples
were fixed in 2.5% glutaraldehyde in 0.1 Mcacodylate buffer for 30
min, postfixed in 2% osmium tetroxide, dehydrated in ethanol, and
embedded in EPON. Sections were viewed in an electron microscope
(model 300; Phillips Sci., Mahwah, NJ).
Chemotaxis assays. Chemotaxis assays were performed in 48-well
microchemotaxis chambers (Neuro Probe, Bethesda, MD) containing
a polycarbonate membrane (5 Am; Nucleopore, Pleasanton, CA). MPs
were suspended in RPMI 1640 containing fetal bovine serum (1%),
and 104 cells were added per well to the upper chamber. The lower
chamber contained the chemotactic stimulus and other agents, as indi-
cated. Assays were performed in triplicate-quadruplicate over a 4-h
incubation period at 37°C, after which nonmigrating cells were re-
moved, membranes were fixed in methanol, and migrating cells were
visualized with Wright's stain. Cells in nine high-power fields were
counted, and the mean and SEMwere determined. The results are
representative of at least two or more replicate experiments.
Assays with AGEs immobilized on the membrane in the chemo-
taxis chamber. These experiments were performed according to the
general method of Aznavoorian et al. (25). In brief, before the chemo-
tactic assay, Nucleopore membranes (5 Arm) were floated on a solution
of AGE-albumin or control albumin (500 nM) in calcium-magne-
sium-free Dulbecco's PBS at 37°C overnight and then air dried. In
certain experiments an 100-fold molar excess of sRAGEwas incubated
for 1 h at 37°C with the AGE-albumin or native albumin-coated mem-
branes. The membranes were then washed and MPmigration assays
were performed with the coated surface of the membrane facing the
upper or lower chamber, as indicated.
Phagokinetic track assays. Cell motility on surfaces coated with
AGE-albumin or native albumin was assayed by the phagokinetic track
technique as described by Albrecht-Buehler (26). Coverslips were
coated with protein by dipping them into solution of AGE-albumin or
native albumin (25 mg/ ml in each case; Sigma Chemical Co.), drain-
ing the coverslip, exposing it to 100% ethanol, and finally drying it in a
stream of hot air. Colloidal gold solution was prepared by mixing 1.8
ml of gold chloride (0.5%; Fischer Scientific, NewYork), 6 ml of so-
dium carbonate (36.5 mM), and 11 ml of double-distilled water, boil-
ing, and then adding 1.8 ml of formaldehyde (0.1%). Gold particles
formed immediately, as indicated by appearance of a reddish-brown
color. Hot gold solution (80-90°C) was added to albumin-coated cov-
erslips in 24-well tissue culture plates, incubated for 45 mm, and then
coverslips were washed twice in cell culture medium. For phagokinetic
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track assays, cells were plated on gold-coated coverslips and incubated
6 h at 370C in a humified atmosphere. At the end of the incubation
period, coverslips were fixed in paraformaldehyde (3.5%) in PBS,
mounted in PBS-glycerol, and viewed by dark-field microscopy. The
same procedure was used to study MPmigration on substrates com-
posed of AGE-collagen I and native collagen I.
Implantation of AGE-derivatized polytetrafluoroethylene (PTFE)
tubes into rats. Tubes of PTFE mesh (diameter, 1 cm; length 2 cm;
90-am pore size; Gortex; generously provided by W. L. Gore, Inc.,
Wakefield, MA) were incubated in solutions containing either AGE-al-
bumin or native albumin (the native albumin had been incubated 6-8
wk at 370C in the absence of glucose), each at a concentration of 500
Mg/ml, for 16 h at 40C. Adsorption of each of these proteins was tested
by inclusion of trace amounts of '251-AGE-albumin or '25I-albumin in
the protein-coating solutions and was found to be comparable. PTFE
tubes were washed extensively in sterile saline and immediately im-
planted into the subcutaneous tissue of rats. At the indicated times, the
dermal layer containing the PTFE tubes was excised, fixed in buffered
Formalin (10%), embedded in paraffin, and sectioned. The sections











Detection of RAGEand the LF-L AGE-bindingprotein in hu-
manMPs. In a previous study to characterize cell surface AGE-
binding proteins, two polypeptides derived from bovine lung
that mediate the interaction of AGEswith endothelium were
identified: RAGEand LF-L AGE-binding protein (10). On
the basis of biochemical and molecular cloning studies, RAGE
is a new member of the immunoglobulin superfamily of recep-
tors that specifically binds AGEsand is present on the surface
of bovine ECs (8, 10). Monospecific polyclonal antibodies
raised to bovine RAGEin guinea pigs were used to detect im-
munoreactive material on Western blots of protein extracted
from membrane-rich fractions of human MPs(Fig. 1 A). Two
bands were visible in the MP-derived fractions, corresponding
to relative molecular masses of 32 and 45 kD (lane 1)
compared with purified bovine lung RAGEin which a single
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Figure 1. Immunoblotting of detergent extracts of MPs with anti-RAGE IgG and anti-LF-L IgG. (A) Anti-RAGE IgG. Detergent extracts of
human MPs(lane 1) and purified RAGE(7.5 Mg) and LF-L (7.5 gg) from bovine lung, respectively (lanes 2 and 3) were subjected to SDS-PAGE
( 10%; nonreduced), electroblotting, and then blots were reacted with anti-RAGE IgG ( 55 gg/ml). Sites of primary antibody binding were visu-
alized with an horseradish peroxidase-conjugated secondary antibody. The same experiment was performed in lanes 4 and 5 (samples were ex-
tract of MPand purified RAGE, respectively), but sRAGE(500 ,g/ml) was added during incubation of the primary antibody with the blot.
(B) Anti-LF-L IgG. MPs solubilized in nonreduced SDS-PAGEsample buffer (lane 1) and purified LF-L (7.5 Mg) and RAGE(7.5 Mg) from
bovine lung, respectively (lanes 2 and 3), were subjected to SDS-PAGE(10%; nonreduced), electroblotting, and then blots were reacted with
anti-LF-L IgG (5 gg/ml). Sites of primary antibody binding were visualized as above. The same experiment was performed in lanes 4 and 5
(samples were extract of MPand purified RAGE, respectively), but soluble LF-L (75 gg/ml) was added during incubation of the primary anti-
body with the blot. (C) Detergent extracts of MPswere adsorbed to either anti-RAGE IgG-affi-gel or anti-LF-L IgG-affi-gel, and the pass-through
or eluates were subjected to Western blotting with anti-RAGE IgG. The pass-through and eluate from the anti-RAGE IgG-affi-gel are shown in
lanes I and 3, respectively. The pass-through and eluate from the anti-LF-L IgG-affi-gel are shown in lanes 2 and 4, respectively. Lanes 5 and 6
contain RAGEor LF-L, respectively, purified from bovine lung. (D) Detergent extracts of MPstreated as in (C) above were subjected to Western
blotting with anti-LF-L IgG. The pass-through and eluate from the anti-LF-L-affi-gel are shown in lanes 1 and 3, respectively, and the pass-
through and eluate from the anti-RAGE IgG-affi-gel are shown in lanes 2 and 4, respectively. Lanes 5 and 6 contain RAGEor LF-L, respectively,
purified from bovine lung. The migration of standard proteins run simultaneously is shown: 97.4 kD (phosphorylase B), 69 kD (bovine serum
albumin), 46 kD (ovalbumin), and 30 kD (carbonic anhydrase). These experiments were repeated at least three times.
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served. In contrast, anti-RAGE IgG did not stain purified LF-L
(lane 3). Addition of excess soluble purified RAGEduring
incubation of blots with anti-RAGE IgG prevented the appear-
ance of the bands from MPsand lung (lanes 4 and 5), indicat-
ing that in each instance these bands resulted from reaction of
the antibody with determinants present in RAGE. However,
the presence of excess soluble LF-L AGE-binding protein did
not diminish the intensity of bands immunoreactive with the
anti-RAGE antibody (data not shown). The presence of two
different size immunoreactive RAGEpolypeptides in extracts
from MPswas a variable finding and probably reflected post-
translational processing/cleavage, as several lower molecular
mass forms of RAGE(from 55 kD and lower) were previously
observed in 293 cells transfected with full-length RAGE
cDNA (8).
In addition to RAGE, our previous study also identified an
LF-L AGE-binding protein in bovine lung extracts that bound
AGEs( 10). This polypeptide was termed the LF-L AGE-bind-
ing protein because of identity of the amino terminal sequence
to lactoferrin, identical mobility on SDS-PAGE, cross-reactiv-
ity of the respective antisera, and comparable AGEbinding
activity of LF-L and lactoferrin. Western blotting of detergent
extracts of MPswith anti-LF-L AGE-binding protein IgG dem-
onstrated a single band with a relative molecular mass of 30
kD (Fig. 1 B, lane I). This band migrates more rapidly than the
purified bovine LF-L AGE-binding protein isolated from lung,
which has a relative molecular mass 80 kD (Fig. 1 B, lane
2). In contrast, purified RAGEcould not be visualized with
anti-LF-L IgG (lane 3). Appearance of the bands from MPs
and lung (lanes I and 2) was due to the presence of antigenic
determinants in LF-L AGE-binding protein from lung, as ad-
dition of excess soluble LF-L (the purified 80-kD polypeptide
form) prevented visualization of this material (lanes 4 and 5).
In contrast, addition of excess RAGEdid not diminish the
intensity of bands immunoreactive with the anti-LF-L AGE-
binding protein antibody (data not shown). The presence of a
more rapidly migrating band in extracts of MPsthat reacts with
anti-LF-L IgG is consistent with previous observations in
which Western blotting of bovine endothelial extracts also
showed a more rapidly migrating band with a relative molecu-
lar mass 30 kD ( 10). Although the mechanism(s) leading to
formation of this material is at present uncertain, it could arise
from proteolytic cleavage of lactoferrin or LF-L (27, 28).
To establish that RAGEand the 30-kD form of LF-L were
distinct molecular entities, detergent extracts of MPswere ad-
sorbed with either affinity-purified anti-LF-L IgG or anti-
RAGEIgG coupled to a solid support (Fig. 1 Cand D). When
the MPlysate was adsorbed with immobilized anti-RAGE IgG,
Western blotting with anti-RAGE IgG revealed (Fig. 1 C) that
the band corresponding to RAGEdisappeared in the pass-
through (lane 1) whereas incubation of anti-RAGE IgG resin
with high salt (NaCl, 1 M) eluted RAGE(lane 3). Complemen-
tary results were obtained when MP lysates were incubated
with immobilized anti-LF-L IgG and immunoblotted with
anti-RAGE IgG; the band corresponding to RAGEremained
present in the pass-through (lane 2) but not in the eluate of the
anti-LF-L IgG affi-gel (lane 4). Western blotting of the same
samples with anti-LF-L IgG (Fig. 1 D) demonstrated disappear-
ance of the band corresponding to LF-L in the pass-through of
anti-LF-L IgG-affi-gel (lane 1) and appearance of this band in
the eluate of the same resin (lane 3). Anti-LF-L IgG visualized
a band corresponding to LF-L in the pass-through of anti-
RAGEIgG-affi-gel (lane 2) and its absence in the eluate from
the same resin (lane 4). These data establish that RAGEand
LF-L derived from MPdetergent extracts are distinct molecu-
lar entities.
Immunofluorescence studies of nonpermeabilized human
MPs to determine if RAGEand LF-L were present on the cell
surface (Fig. 2) revealed a diffuse pattern of surface staining
with anti-RAGE and anti-LF-L antibody (Fig. 2, B and C,
respectively) as compared with nonimmune IgG controls (Fig.
2A).
RAGEand the LF-L AGE-binding protein mediate the
binding and internalization of 25I-AGE-albumin. In view of
the presence of RAGEand LF-L on the surface of human MPs,
we considered whether they could mediate the interaction with
soluble AGEs. '25I-AGE-albumin bound to MPs at 4VC in a
dose-dependent manner, Kd 80 nM (Fig. 3 A) comparable
Figure 2. Detection of AGE-binding proteins on mononuclear phagocytes by indirect immunofluorescence. MPswere stained with nonimmune
guinea pig IgG (A), anti-RAGE IgG (B), or anti-LF-L IgG (C) as described in the text. x650. These experiments were repeated at least three
times.
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mg/ml), or nonimmune IgG ( 1:1 = 2.7 mg/ml) for 2 h at 4VC, and then a radioligand binding assay was performed at 4VC employing 125[I
AGE-albumin alone ( 100 nM) or in the presence of a 20-fold excess of unlabeled AGE-albumin. Maximal specific binding ( 100%), defined in
the presence of nonimmune IgG ( 1: 1 ), was binding observed in wells incubated with 1251-AGE-albumin alone minus binding observed in wells
incubated with '25I-AGE-albumin in the presence of unlabeled material. Results shown are the mean±SE of at least quadruplicate determina-
tions. The far right bar depicts the effect of adding excess glucose-6-phosphate (25 mM)on the observed binding. (C) MPswere preincubated
with the indicated dilution of anti-LF-L IgG ( 1: 1 = 2.5 mg/ml), anti-CD4 IgG ( 1: 1 = 2.7 mg/ml), or nonimmune IgG ( 1: 1 = 2.7 mg/ml) and
the assay was carried out as in B, above. The far right bar depicts the effect of adding excess glucose-6-phosphate (25 mM)on the observed
binding. (D) MPswere preincubated with 1: 1 dilutions of antibodies as above, and the radioligand binding assay was performed in the presence
of '251-AGE albumin (100 nM) prepared by incubating ribose with albumin. The far right bar depicts the effect of adding excess ribose (25
mM)on the observed binding. (E) MPswere preincubated with 1: 1 dilutions of antibodies as above and AGEalbumin (1 00 nM) was prepared
by incubating glucose with albumin. The far right bar depicts the effect of adding excess of glucose (25 mM)on the observed binding. The
experiments were repeated at least five times.
to what has been previously reported (29). The latter experi-
ment used AGE-albumin prepared with glucose-6-phosphate,
but similar results were obtained with glycated albumin pre-
pared with glucose or ribose (data not shown). Addition of
antibody to RAGElargely blocked the binding of 251I-AGE-al-
bumin to MPs(Fig. 3 B); this was true with 1251-glucose-6-phos-
phate albumin (Fig. 3 B), '251I-ribose albumin (Fig. 3 D), and
1251-glucose albumin (Fig. 3 E). Inhibition of '251-AGE-albu-
min binding to MPswas a specific effect of the immune IgG, as
it was not observed with the same amount of nonimmune IgG
or antibody to another MPsurface protein, CD4(Fig. 3, B-E).
High concentrations of antibody were required for effective
blocking of '25I-AGE-albumin-monocyte binding, presumably
because of immunologic differences between bovine RAGE(to
which the antibody was prepared) and human RAGE(with
which the antibody is reacting on human MPs).
Antibody to the LF-L AGE-binding protein also inhibited
the binding of 1251-AGE-albumin to MPsat 4VC (Fig. 3, C-E)
using glycated albumin prepared in the presence of
glucose-6-phosphate (Fig. 3 C), ribose (Fig. 3 D), or glucose
(Fig. 3 E). As with anti-bovine RAGEIgG, high concentra-
tions of antibody were required for maximal inhibition. These
data indicate that antibodies raised to bovine lung RAGEand
LF-L react with their human counterparts and that RAGEand
LF-L mediate binding of '25I-AGE-albumin to human MPsat
4VC. In all cases the unlabeled aldose sugars (glucose-6-phos-
phate, ribose, or glucose alone) did not compete with 125[1
AGE-albumin for binding to MPs (Figs. 3, B-E).
If RAGEand LF-L comprise the MPsurface binding site
for AGEs, they should mediate the binding and internalization
of AGEsat 370C. To examine these issues, cell-associated AGE
albumin was localized to a cell surface or an internalized/en-
docytosed pool. Radioligand binding experiments with 12511
AGEalbumin (prepared with glucose-6-phosphate) and MPs
at 4VC demonstrated comparable elution of specifically bound
radioactivity by exposure of cells to acidic buffer, heparin, dex-
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Figure 4. Cell-associated '25I-AGE-albumin (prepared by incubating albumin with glucose-6-phosphate) is bound to the cell surface at 4VC (A)
and internalized 370C (B and C) via interaction with RAGEand LF-L. (A) MPswere incubated with '25I-AGE albumin (100 nM) at 4VC for
3 h, cultures were washed, and cell-associated radioligand was dissociated by exposure to buffer containing heparin, acid, dextran sulfate, trypsin,
or detergent (Nonidet P-40), as described in the text. Results shown are the mean±SE of at least quadruplicate determinations. (B) MPswere
incubated with '251-AGE albumin ( 100 nM) at 370C for 3 h. After washing, cell-bound '251I-AGE albumin was eluted with buffer containing either
heparin or trypsin, followed by detergent, as described in the text. Results shown are the mean±SE of at least quadruplicate determinations.
(C) MPswere incubated with 1251-AGE-albumin alone (100 nM; total binding) or in the presence of 20-fold molar excess of unlabeled AGE-al-
bumin (nonspecific binding) for the indicated times at 37"C. As indicated (+Ab), immune IgG to both RAGEand LF-L (final concentration
of each, 1.4 and 1.35 mg/ml, respectively) were preincubated with MPs for 1 h at 4VC. Then cultures were washed, and surface-bound radioac-
tivity was eluted with heparin-containing buffer (solid lines), and internalized radioactivity (dashed lines) was determined by subsequent deter-
gent solubilization of the cultures. Data shown represent specific binding (total minus nonspecific binding), the mean of duplicate determina-
tions. Nonimmune IgG at the same concentration as anti-AGE-binding protein IgGs had no effect on '251I-AGE-albumin binding/internalization
by MPs in this assay. The experiments were repeated at least two times.
tran sulfate, trypsin, or detergent (Fig. 4 A). At 370C (Fig. 4 B)
incubation of MPswith 125I-AGE-albumin also led to the for-
mation of a cell surface-associated pool of cell-bound radioli-
Figure 5. Binding and uptake of AGEalbumin conjugated to colloidal
gold particles by MPs. Incubation of MPs with colloidal gold (25
nm) conjugated to AGEalbumin (500 nM) at 370C results in binding
to the cell surface (A) and subsequent internalization via endocytosis,
where it is localized to membrane-bound vesicles and components
of the lysosomal compartment (B). X 19,000. The experiment was
repeated twice.
gand that could be eluted by exposure of cultures to buffer
containing heparin or trypsin treatment. However, at the
higher temperature, there was an additional pool of specifically
cell-associated radioligand that remained after elution with hep-
arin or trypsin (Fig. 4 B) and was not observed in experiments
performed at 40C (at the lower temperature, the pool of 125i-
AGE-albumin released from the cell by heparin, trypsin, or
detergent coincided exactly). This additional cell-associated
1251-AGE-albumin observed at 370C was released by dissolu-
tion of the cells in detergent-containing buffer. Ultrastructural
studies with AGE-albumin colloidal gold conjugates con-
firmed that at 370C a pool of ligand was present on the cell
surface (Fig. 5 A) from which it could be eluted with any of the
treatments described above, as well as a pool of internalized
ligand (Fig. 5 B). The latter was found in membrane-bound
vesicles and these internalized AGE-albumin gold conjugates
were eluted by dissolution of the cells in detergent (data not
shown).
On the basis of this analysis of the localization of cell-asso-
ciated AGE-albumin, studies were performed to determine if
anti-RAGE IgG and anti-LF-L IgG would block binding of
251I-AGE-albumin to MPsat 370C. Preincubation of MPswith
simultaneously added anti-RAGE IgG and anti-LF-L IgG at
40C blocked surface binding of 1251I-AGE albumin at 370C
(Fig. 4 C), defined in this experiment as heparin-elutable radio-
activity. The presence of antibodies to the AGE-binding pro-
teins also prevented formation ofthe pool of endocytosed radio-
activity (Fig. 4 C), defined as cell-associated material remain-
ing after elution of surface-bound '251-AGE-albumin.
Soluble AGE-albumin induces chemotaxis of MPsthrough
interaction of AGE-moieties with RAGEand the LF-L AGE-
binding protein. In view of the deposition of AGEsin the vascu-
lature and the hypothesis that they could contribute to the
pathogenesis of vessel wall lesions ( 1 ), we sought to understand
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mechanisms underlying their effect on MPmigration. Our pre-
vious work has shown that soluble AGE-albumin (6) as well as
other AGE-modified proteins induced chemotaxis of MPs,
leading us to compare the effects of glycated albumin prepared
with glucose-6-phosphate, glucose, or ribose (Fig. 6, A-C, re-
spectively) on monocyte migration. Checkerboard analysis
demonstrated that each of the glycated albumin preparations
induced MPchemotaxis over a similar range of concentra-
tions. When the sugars used for glycation were placed in the
lower compartment of the chemotaxis chamber, they did not
induce MPmigration (Fig. 6, A-C, top-most bar). Similarly,
native albumin was devoid of MPchemotactic activity.
These experiments demonstrated that albumin glycated in
the presence of glucose-6-phosphate, glucose, or ribose in vitro
was chemotactic for MPs. To determine if these results could
be extrapolated to glycated proteins that formed in vivo, AGEs
from diabetic plasma, which was positive for AGEantigen by
ELISA, were purified by immunoaffinity chromatography
with antibody selective for the AGE-moiety linked to affi-gel.
These patient-derived AGEsalso induced MPchemotaxis (Fig.
6 D). Whenplasma from young healthy individuals was sub-
jected to the same purification procedure, negligible AGE-im-
munoreactive material/protein was obtained and no MPche-
motactic activity was observed (data not shown).
Our next goal was to determine whether RAGEand LF-L


















AGEs. WhenMPswere preincubated with anti-RAGE IgG at
4VC, washed, warmed to 370C, and then placed in the upper
compartment of the chemotaxis chamber, the migratory re-
sponse to glucose-6-phosphate-albumin was blocked in a dose-
dependent manner (Fig. 7 A). Migration of MPsin response to
soluble glucose-albumin, ribose-albumin, or patient-derived
AGEswas also blocked by anti-RAGE IgG (Fig. 7, B-D, respec-
tively). F(ab')2 fragments prepared from anti-RAGE IgG had
a similar inhibitory effect on MPchemotaxis to AGE-albumin
(Fig. 7 A), though neither anti-RAGE IgG nor the F(ab')2
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Figure 6. Effect of soluble AGEs on MPchemotaxis: experiments
with AGEsprepared by incubating albumin with either
glucose-6-phosphate (A), glucose (B), ribose (C), or AGEsderived
from diabetic patient plasma (D). The indicated concentration of
AGEalbumin (nM) (A-C) or AGEs from diabetic plasma (,ug/ml)
was added to either the upper or lower compartment of the chemo-
taxis chamber, MPs were added to the upper compartment and the
migration assay was performed as described in the text. The upper
line in A-C demonstrates the results when either glucose-6-phosphate
(Glu-6-P04), glucose, or ribose, respectively, was added to the lower
compartment of the chamber at a concentration of 250 mM. Positive
controls employed FMLP( 10 -6 M) added to the lower compartment.
The x-axis represents the average number of cells in nine high-pow-
ered fields that had migrated across the membrane. The mean±SEM
of triplicate determinations is shown and the experiments were re-
peated at least 3 times.
Figure 7. Effect of anti-AGE-binding protein IgG on MPchemotaxis
induced by soluble AGE/glycated albumin prepared by incubating
albumin with either glucose-6-phosphate (A), glucose (B), ribose
(C), or AGEsderived from diabetic plasma (D). (A) MPs freshly
harvested from human blood were suspended (106 cells/ ml) in RPMI
1640 containing fetal bovine serum (1%) and preincubated with the
indicated concentration of anti-RAGE IgG or F(ab')2, nonimmune
IgG (NI), or anti-CD4 IgG (a-CD4) for I h at 4°C were washed twice
in balanced salt solution, and then 104 cells were added to the upper
wells of chemotaxis chambers. MPmigration was initiated by adding
either soluble AGE-albumin (AGE; 50 nM) or FMLP( 10 6 M) to
the lower well as the chemotactic stimulus. Chambers were incubated
at 37°C in a humidified atmosphere for 4 h, and then membranes
were washed, fixed in methanol, and Wright stained. The x-axis rep-
resents the average number of cells in nine high-powered fields that
had migrated across the membrane. The mean±SEMof triplicate de-
terminations is shown. (B-D) Experiments were performed accord-
ing to the same protocol as above (A) in which the stimulus for MP
migration was AGEalbumin prepared in the presence of glucose (B),
ribose (C), or AGEsderived from patient plasma (D). The concen-
tration of AGEsprepared in vitro was 50 nM (A-C) and the concen-
tration of patient-derived AGEswas 30 ,g/ml (D). The antibodies
were employed at a concentration of 20 ,g/ml. The experiments were
repeated at least three times.
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Figure 8. Effect of sRAGEon MPchemotaxis induced by soluble
AGE-albumin (prepared in the presence of glucose-6-phosphate).
sRAGE(25 ztM) was preincubated with AGE-albumin (250 nM) or
FMLP(1 qM) for 1 h at 370C, and then the reaction mixture was
added to the lower compartment of the chemotaxis chamber. Con-
trols included experiments performed with either sRAGEalone or
the buffer in which sRAGEwas dissolved (PBS containing octyl-fl-
glucoside, 0.0 1% or PBS-D) or FMLP( o0-6 M). The response to
FMLP( 10-6 M) alone was comparable to that observed with FMLP
+ PBS-D or sRAGE. The chemotaxis assay was performed and as-
sessed as in Figs. 6 and 7 above. These experiments were performed
at least three times.
Control experiments with nonimmune IgG and polyclonal IgG
to CD4 in place of antibodies to RAGEand LF-L had no effect
on MPmigration in response to AGE-albumin (Fig. 7, A-D).
These observations suggested that interaction of AGEswith
monocyte RAGEwas necessary to initiate chemotaxis in re-
sponse to soluble AGE-albumin. Supporting this hypothesis,
addition of soluble RAGE, which should block interaction of
AGEs with their receptors on the surface of MPs, prevented
AGE-induced migration (Fig. 8). For this experiment, excess
sRAGEwas preincubated with AGE-albumin for 1 h at 370C,
the mixture was added to the lower compartment of the che-
motaxis chamber, and subsequent migration of MPs in re-
sponse to soluble AGE-albumin was blocked. In contrast,
sRAGEhad no effect on the migration of MPs in response to
the chemotactic stimulus FMLP(Fig. 8).
These data, which suggested a role for RAGEin mediating
MPmigration in response to AGE-albumin, led us to test the
effect of preincubation of MPs with anti-LF-L IgG (Fig. 7,
B-D and Fig. 9). IgG to the LF-L AGE-binding protein also
blocked MPmigration to AGE-albumin prepared with glu-
cose-6-phosphate in a dose-dependent manner (Fig. 9, lines
2-4). F(ab')2 fragments prepared from anti-LF-L IgG had a
similar inhibitory effect on MP migration (Fig. 9, line 7)
whereas neither of these immunologic reagents altered MPmi-
gration to FMLP(Fig. 9, lines 5 and 8, respectively). In addi-
tion, nonimmune IgG at the same concentration had no effect
on MPmigration in response to AGE-albumin or FMLPadded
to the lower compartment of the chemotaxis chamber (Fig. 9,
lines 9 and 10, respectively). Antibody to LF-L similarly inhib-
ited MPchemotaxis in response to AGE-albumin glycated with
glucose, ribose, or to AGEs derived from diabetic patient
plasma (Fig. 7, B-D, line four in each case, respectively).
Taken together these observations are consistent with the
hypothesis that access of the AGEligand to RAGEand LF-L
on the MPwas required for MPmigration to occur in response
to soluble AGE-albumin. To explore further the nature of the
ligand mediating chemotaxis, we found that preincubation of
AGE-albumin, either preparations made by incubating albu-
min with glucose-6-phosphate, glucose, or ribose with albu-
min, with anti-AGE IgG blocked MPmigration in a manner
dependent on the antibody concentration used (Fig. 10, A-C,
respectively). Anti-AGE antibody (Fig. 10 A) and the same
concentration of nonimmune IgG (designated NI, the second
line in Fig. 10, B-D) had no effect on the migration of MPs in
response to FMLP. In addition, the anti-AGE antibody
blocked chemotaxis in response to AGEs purified from dia-
betic plasma (Fig. 10 D). This is consistent with our recent
observations that the anti-AGE antibody blocked the binding
of AGEs to cellular surfaces (Yan, S. D., A. M. Schmidt, J.
Brett, and D. Stem, manuscript in preparation).
Immobilized AGEsattenuate migration of MPs. Accumu-
lation of MPs in the subendothelium is thought to have a cen-
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Figure 9. Effect of anti-LF-L IgG and
F(ab')2 on MPchemotaxis induced by
AGEalbumin (prepared in the presence of
glucose-6-phosphate). The same experi-
mental protocol was followed as in Figs. 6
and 7 above, except that anti-LF-L
AGE-binding protein IgG or F(ab')2 was
used. These experiments were performed
at least three times. The chemotactic re-
sponse of MPs to glucose-6-phosphate al-
bumin in the absence of antibodies was
50 60 identical to the response observed with
nonimmune IgG (line 9).
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Figure 10. Effect of anti-AGE IgG (a-AGE) on the chemotactic re-
sponse of human MPsto AGEalbumin prepared by incubating al-
bumin with glucose-6-phosphate (A), glucose (B), ribose (C), or
AGEsderived from diabetic patient plasma (D). (A) MPswere added
to chemotaxis chambers containing AGEalbumin (50 nM) alone or
AGEalbumin preincubated for I h at 370C with the indicated con-
centration of anti-AGE IgG in the lower compartment. Positive con-
trols employed FMLP( 10-6 M) added to the lower compartment of
the chamber. Chemotaxis assays were performed as described above.
(B-D) The same experiment was performed in B and Cusing albu-
min glycated in the presence of glucose (B) or ribose (C) at a final
AGEalbumin concentration of 50 nM. Antibodies, either anti-AGE
(a-AGE) or nonimmune (NI), each at a concentration of 13 ,g/ml,
were added to the lower compartment of the chemotaxis chamber as
above (A). Native albumin (50 nM) and glucose or ribose (each at
a concentration of 250 mM)were added to the lower compartment
of the chamber as indicated. In D, the same experimental protocol
was followed with AGEsderived from the diabetic plasma. These ex-
periments were repeated two to three times.
atherosclerosis (30). For AGEs to contribute to the retention
of MPs in the vasculature, under certain conditions, such as
following their immobilization in the extracellular matrix, they
would have to block migration of MPs. To test this, AGE-albu-
min was immobilized on the upper surface of a membrane in a
chemotaxis chamber and the migratory response of MPsto the
stimulus FMLP(the latter added to the bottom well) was stud-
ied (Fig. 11 ). For these and the other studies reported below
results are reported only with AGE-albumin preparations pre-
pared with glucose-6-phosphate, since the cellular interactions
of glycated albumin preparations made with glucose-6-phos-
phate, glucose, or ribose, as well as patient-derived AGEs, ap-
pear to be comparable. Whenthe upper surface of the chemo-
taxis chamber membrane was coated with native albumin, mi-
gration in response to FMLPoccurred in a dose-dependent
manner, with increasing numbers of MPs appearing in the
lower chamber (Fig. 1 1, lines 1-4). In contrast, when AGE-al-
bumin was adsorbed to the upper surface of the chemotaxis
chamber membrane, MPmigration in response to FMLPwas
considerably reduced (Fig. 11, lines 5-7).
To assess if the inhibitory effect of immobilized AGE-albu-
min on MPmigration to FMLPwas due to interaction of the
ligand with AGE-binding proteins on the MPsurface, the effect
of antibodies to RAGEand LF-L was studied (Fig. 12). Prein-
cubation of MPswith either anti-RAGE IgG (Fig. 12, line 6),
anti-LF-L IgG (Fig. 12, line 7), or both of these immune IgGs
(Fig. 12, line 8) increased MPmigration to the lower chamber
in response to FMLP. A similar inhibitory effect was observed
with F(ab')2 fragments derived from anti-RAGE IgG and anti-
LF-L IgG (Fig. 12, lines 9-11). Control experiments demon-
strated that AGE-albumin, but not native albumin, had to be
present on the upper surface of the chemotaxis chamber for
arrest of MPmigration in response to FMLPto occur (Fig. 12,
lines 1-4). Furthermore, preincubation of MPs with nonim-
mune IgG (in place of anti-AGE-binding protein IgG) did not
alter MPmigration (Fig. 12, line 5). These results predict that
interference with the interaction of the immobilized glycated
proteins with the AGE-binding proteins would block the effect
of AGEs. Consistent with this hypothesis, addition of sRAGE
to the membranes coated with AGE-albumin restored chemo-
taxis in response to FMLP(Fig. 13).
These data suggested that when migrating MPs interact
with immobilized AGEs their motion is slowed. Phagokinetic
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Figure 11. Effect of AGEalbumin bound to the membrane in the chemotaxis chamber on MPmigration in response to FMLP. HumanMPs(104
cells per well) were placed in the upper wells of chemotaxis chambers in which the upper surface of the membranes had been coated with either
AGEalbumin (prepared in the presence of glucose-6-phosphate) or native albumin (500 nM). Then, the chemotactic peptide FMLP, at the in-
dicated concentrations, was added to the lower compartment. The mean and SEMof quadruplicate determinations is shown and the experiments
were repeated at least three times.












I I a a a ____j
Downloaded from http://www.jci.org on May  4, 2015.   http://dx.doi.org/10.1172/JCI116442
Adsorbed to upper FMLPadded





































Figure 12. Antibodies to AGE-binding proteins restore the chemotactic response to FMLP in the presence of membranes coated with AGE
albumin (prepared in the presence of glucose-6-phosphate). MPswere preincubated for 1 h at 4VC with either anti-RAGE IgG (20 jg/ml),
anti-LF-L (20 ,ug/ml), both antibodies together (anti-RAGE IgG, 20 tg/ml; anti-LF-L IgG, 20 Atg/ml), or nonimmune IgG (20 ,tg/ml). Where
indicated, F(ab')2 fragments were used in place of IgGs at the same concentration. Cells were then washed in balanced salt solution and resus-
pended at the same cell density in RPMI 1640 containing fetal bovine serum (1%). The chemotaxis assay was then performed by adding FMLP
(10-6 M) to the lower well of the chambers and the experiments were repeated at least three times.
gration on an AGE-derivatized surface. WhenMPswere plated
on coverslips coated with native albumin that had been over-
laid with colloidal gold, long paths of migration were evident
(Fig. 14 A, left). In contrast, when AGE-albumin was used in
place of the native molecule, the tracks were much shorter (Fig.
14 B, right). Experiments with coverslips coated with AGE-
collagen I also showed a similar reduction in the length of MP
tracks compared with controls with native collagen I (data not
shown).
In vivo model of AGEdeposition. PTFE tubes with ad-
sorbed AGE-albumin or native albumin provide a surface
which very slowly releases the proteins over days (Fig. 15 A).
Thus, this system consists of both low concentrations of soluble
Adsorbed to upper FMLPadded
surface of membrane to lower well











protein dissociating from the mesh, in addition to the same
proteins immobilized on the PTFE substrate. Subcutaneous
placement of native albumin-PTFE tubes incited virtually no
cellular response, except for some at the PTFE-tissue interface,
seen after 4 d of implantation (Fig. 15 B). In contrast, PTFE
tubes with AGEs implanted for the same time incited a florid
mononuclear cellular infiltrate: in Fig. 15 C, mononuclear cells
are shown moving through the interstices of the PTFE mesh.
Many of the monocytes trapped within the PTFEmesh display
leukoclastic changes at higher magnification (Fig. 15 D). After
8 d of implantation, a florid foreign body-type granulomatous
response is seen primarily at the interface of PTFE tubes im-
pregnated with native albumin (Fig. 15 E). PTFE tubes with
1u zu 3u 4u
CELL NUMBER
Ou W.
Figure 13. sRAGErestores the chemotactic response to FMLPin the presence of membranes coated with AGEalbumin (prepared in the pres-
ence of glucose-6-phosphate). sRAGE( 1 00-fold molar excess over AGEcoating the membrane surface) was incubated with membranes previ-
ously coated with-native albumin or AGEalbumin, and then a chemotaxis assay was performed as above with FMLPas the stimulus in the lower
chamber. The mean±SEMof quadruplicate determinations is shown and the experiments were repeated at least three times.
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Figure 14. Phagokinetic track assay: MPmigration on
matrix composed of native albumin or AGEalbumin
(prepared in the presence of glucose-6-phosphate). MPs
were allowed to migrate for 6 h on matrixes of native
albumin or AGE-albumin (left and right, respectively)
which had been coated with colloidal gold particles.
The dark tracks left by locomoting MPs are visualized
by dark-field microscopy. X 125. The experiment was
repeated at least three times.
adsorbed AGEsare filled with mononuclear cells (Fig. 15 F),
many of which show epithelioid changes (Fig. 15 G).
Discussion
The results of our studies delineate a model ligand-receptor
system that affects MPmigration. The ligands are heteroge-
neous nonenzymatically glycated proteins termed AGEs. Simi-
lar binding of radioiodinated AGEs to the MPsurface and
modulation of monocyte migration was observed with AGE-
albumin prepared by incubating albumin with glucose, glu-
cose-6-phosphate, or ribose, as well as with AGEspurified from
diabetic plasma. Wehave shown that there is a major differ-
ence, however, between the effects of soluble AGE-albumin,
used as a prototypic compound for AGEs detected in blood
(31), and AGE-albumin/AGE-collagen I adsorbed to sub-
strates, used as models for insoluble AGEs immobilized on
long-lived structures in the basement membrane. Soluble
AGEsinduce MPmigration, presumably in response to a con-
centration gradient formed by diffusion from the lower com-
partment of the chemotaxis chamber. In contrast, immobilized
AGEsslow monocyte migration, presumably through engage-
ment of AGEreceptors. This marked difference in the cellular
response to soluble versus immobilized ligand may provide
important insight into the contribution of AGEs to certain
pathological situations in vivo. In the tissues, insoluble AGEs
have been localized to extracellular matrixes, whereas only
small amounts of soluble AGEswould be present, since most
are cleared rapidly from the intravascular space (1 1, 32). De-
fective wound healing in genetically diabetic mice is due in part
to a delayed and decreased early cellular response, including
decreased migration of mononuclear phagocytes (33). This
leads us to speculate that matrix-associated AGEscould attenu-
ate MPmigration into a wound, retarding subsequent cellular
events promoting repair.
The cellular acceptor site for AGEs involves two polypep-
tides, RAGEand LF-L. Although the mode of association of
these two proteins on the cell surface has not been clarified,
recent studies demonstrating that LF-L binds to RAGEin a
noncovalent high affinity fashion (34) suggest the following
model: RAGE, an integral membrane protein, is anchored on
the cell surface and interacts with LF-L from that site. In sup-
port of this hypothesis, antibodies to either RAGEor LF-L
largely blocked the binding of '25I-AGE-albumin to human
MPs (Figs. 3 and 4) and bovine endothelial cells (10). The
concept of two closely associated cell surface AGE-binding
proteins is also consistent with studies of Yang et al. ( 1) in a
rat system, where antibodies to either one of two AGE-binding
proteins blocked binding of AGEligands. It should be noted
that the sequence of the two AGE-binding proteins reported by
Yang et al. ( 11) is different than RAGEand LF-L, indicating
that they are likely to be distinct.
The central role of the cellular AGE-binding proteins in
modulating MPchemotaxis in response to either soluble or
immobilized AGE-albumin was shown in studies with specific
antibodies to RAGEand LF-L as well as their F(ab')2 frag-
ments. Two additional lines of evidence suggest a close rela-
tionship between binding of AGEs to cell surface RAGEand
LF-L and changes in MPmigration: doses of AGE-albumin
that stimulate chemotaxis are similar to those that result in
occupancy of AGE-binding sites on MPs(Fig. 3 and Kirstein et
al. [6]), and soluble RAGE, which blocks the interaction of
AGEswith cellular surfaces (32), prevents the effects of AGEs
on MPmigration. Of note is that higher concentrations of anti-
body were required to block the binding of '251-AGE-albumin
to MPscompared with the concentrations of antibody required
to inhibit AGE-stimulated MPmigration. A possible explana-
tion for the difference in concentrations of antibodies required
to alter MPmigration and binding of radiolabeled AGE-albu-
min might be that engagement of a limited number of receptors
by either of the antibodies blocks ligand-induced activation of a
critical (i.e., threshold) number of receptors. Further studies
will be required to test this hypothesis.
The ability of AGEs to modulate MPmigration indicates
one way in which these glycated proteins might contribute to
the pathogenesis of vascular lesions: soluble AGEs loosely
bound to the vessel can attract AGEs to the vessel wall and
immobilized matrix-associated AGEs in the subendothelium
could retain MPsand lead to their activation (6, 7). This con-
cept is supported by studies of Vlassara et al. (12) indicating
that infusion of high concentrations of AGE-albumin leads to
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Figure 15. Implantation of PTFE tubes with adsorbed AGEalbumin into rats. PTFE tubes were impregnated with either AGEalbumin (prepared
in the presence of glucose-6-phosphate) or native albumin as described in the text. In A, the protein solutions also contained trace amounts of
'25I-AGE-albumin (closed circle) or '25I-native albumin (open circle). PTFE tubes were then incubated for the indicated times in saline and the
percent of radiolabel remaining adsorbed compared with that present initially ( TO), was determined. In B-G, PTFE tubes with adsorbed native
albumin (B, E) or AGE-albumin (C and D, F and G) were implanted into the subcutaneous tissue of a rat. The tubes were removed after 4
(B-D) or 8 d (E-G) and examined for the presence of infiltrating cells (hematoxylin and eosin staining). D and G are higher power views of
fields from PTFE tubes impregnated with AGE-albumin implanted for 4 or 8 d, respectively. B and Cand Eand F, Xl 10; Dand G, x 280. The
experiment was repeated three times.
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